Zhi-Jie Liu
Auto-generated profile, based on publicly available information

Zhi-Jie Liu

Human Institute, ShanghaiTech University, Shanghai, China

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 December 2019 in eLife
Verified
Journal Article
Open access
QZQingtong Zhou
Qingtong Zhou
DYDehua Yang
Dehua Yang
MWMeng Wu
Meng Wu
YGYu Guo
Yu Guo
WGWanjing Guo
Wanjing Guo
SZSuwen Zhao
Suwen Zhao
Class A G-protein-coupled receptors (GPCRs) influence virtually every aspect of human physiology. Understanding receptor activation mechanism is critical for discovering novel therapeutics since about one-third of all marketed drugs target members of this family. GPCR activation is an allosteric process that couples agonist binding to G-protein recruitment, with the hallmark outward movement of transmembrane helix 6 (TM6). However, what leads to TM6 movement and the key residue level changes of this movement remain less well understood. Here, we report a framework to quantify conformational changes. By analyzing the conformational changes in 234 structures from 45 class A GPCRs, we discovered a common GPCR activation pathway comprising of 34 residue pairs and 35 residues. The pathway unifies previous findings into a common activation mechanism and strings together the scattered key motifs such as CWxP, DRY, Na+ pocket, NPxxY and PIF, thereby directly linking the bottom of ligand-binding pocket with G-protein coupling region. Site-directed mutagenesis experiments support this proposition and reveal that rational mutations of residues in this pathway can be used to obtain receptors that are constitutively active or inactive. The common activation pathway provides the mechanistic interpretation of constitutively activating, inactivating and disease mutations. As a module responsible for activation, the common pathway allows for decoupling of the evolution of the ligand binding site and G-protein-binding region. Such an architecture might have facilitated GPCRs to emerge as a highly successful family of proteins for signal transduction in nature.

1 October 2016 in Cell
Verified
Journal Article
Closed access
THTian Hua
Tian Hua
KVKiran Vemuri
Kiran Vemuri
MPMengchen Pu
Mengchen Pu
LQLu Qu
Lu Qu
GHGye Won Han
Gye Won Han
ZLZhi-Jie Liu
Zhi-Jie Liu

5 July 2017 in Nature
Verified
Journal Article
Closed access
PDF file
THTian Hua
Tian Hua
KVKiran Vemuri
Kiran Vemuri
SNSpyros P. Nikas
Spyros P. Nikas
RLRobert B. Laprairie
Robert B. Laprairie
YWYiran Wu
Yiran Wu
ZLZhi-Jie Liu
Zhi-Jie Liu

1 January 2019 in Cell
Verified
Journal Article
Closed access
XLXiaoting Li
Xiaoting Li
THTian Hua
Tian Hua
KVKiran Vemuri
Kiran Vemuri
JHJo-Hao Ho
Jo-Hao Ho
YWYiran Wu
Yiran Wu
ZLZhi-Jie Liu
Zhi-Jie Liu

1 February 2020 in Cell
Verified
Journal Article
Closed access
THTian Hua
Tian Hua
XLXiaoting Li
Xiaoting Li
LWLijie Wu
Lijie Wu
CIChristos Iliopoulos-Tsoutsouvas
Christos Iliopoulos-Tsoutsouvas
YWYuxia Wang
Yuxia Wang
ZLZhi-Jie Liu
Zhi-Jie Liu

24 May 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
KAKangsa Amporndanai
Kangsa Amporndanai
XMXiaoli Meng
Xiaoli Meng
WSWeijuan Shang
Weijuan Shang
ZJZhenmig Jin
Zhenmig Jin
MRMichael Rogers
Michael Rogers
SHS. Samar Hasnain
S. Samar Hasnain
The SARS-CoV-2 pandemic has triggered global efforts to develop therapeutics. The main protease of SARS-CoV-2 (Mpro), critical for viral replication, is a key target for therapeutic development. An organoselenium drug called ebselen has been demonstrated to have potent Mpro inhibition and antiviral activity. We have examined the binding modes of ebselen and its derivative in Mpro via high resolution co-crystallography and investigated their chemical reactivity via mass spectrometry. Stronger Mpro inhibition than ebselen and potent ability to rescue infected cells were observed for a number of derivatives. A free selenium atom bound with cysteine of catalytic dyad has been revealed in crystallographic structures of Mpro with ebselen and MR6-31-2 suggesting hydrolysis of the enzyme bound organoselenium covalent adduct and formation of a phenolic by-product, confirmed by mass spectrometry. The target engagement with selenation mechanism of inhibition suggests wider therapeutic applications of these compounds against SARS-CoV-2 and other zoonotic beta-corona viruses.